Evidence map›Paper›PMID 41133485›Full record

ReviewEuropean burn journal2025

Managing Infections in Burn Patients: Strategies and Considerations for Antimicrobial Dosing.

Abdullah F Alharthi, Khalid Al Sulaiman, Sultan Alotaibi, Rahaf Alqahtani, Nader Damfu, Aisha Alharbi, Sufyan Alomair, Haifa A Alhaidal, Ohoud Aljuhani

Abstract readReview
In one paragraph

Review in European burn journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. [Research on the pharmacokinetics of linezolid in burn patients].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026
    Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Abdullah F AlharthiDepartment of Clinical Pharmacy, College of Pharmacy, Shaqra University, Al-Dawadmi Campus, Al-Dawadmi 11961, Saudi Arabia.
Khalid Al SulaimanPharmaceutical Care Services, King Abdulaziz Medical, Riyadh 11481, Saudi Arabia.ORCID 0000-0002-5547-2043
Sultan AlotaibiPharmaceutical Care Services, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah 22384, Saudi Arabia.
Rahaf AlqahtaniPharmaceutical Care Services, King Abdulaziz Medical, Riyadh 11481, Saudi Arabia.
Nader DamfuKing Abdullah International Medical Research Center, Jeddah 22384, Saudi Arabia.
Aisha AlharbiPharmaceutical Care Services, King Abdulaziz Medical City, Ministry of the National Guard-Health Affairs, Jeddah 22384, Saudi Arabia.ORCID 0000-0001-9981-3666
Sufyan AlomairDepartment of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Al-Ahsa 36362, Saudi Arabia.
Haifa A AlhaidalPharmaceutical Services Administration, King Saud Medical City, Riyadh 12746, Saudi Arabia.
Ohoud AljuhaniDepartment of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 22252, Saudi Arabia.ORCID 0000-0002-8078-564X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Burn injuries are a major cause of morbidity and mortality, largely due to complications such as infection. Impairment of the immune system following burns increases susceptibility to both internal and external infections, underscoring the need for effective infection control strategies in burn care. In addition, burn patients frequently exhibit profound alterations in drug pharmacokinetics and pharmacodynamics (PK/PD), particularly during the resuscitation and hypermetabolic phases. In the resuscitation phase, increased capillary permeability and reduced cardiac output can prolong drug distribution, delay therapeutic response, lower peak plasma concentrations, and slow elimination. In contrast, the hypermetabolic phase is characterized by elevated catecholamine levels and enhanced tissue perfusion, which accelerate drug distribution and clearance. These physiological changes often necessitate antimicrobial dose adjustments to maintain therapeutic efficacy. This review emphasizes the critical importance of infection prevention and management in burn patients, with a focus on optimizing antimicrobial dosing and therapeutic monitoring in the context of PK/PD alterations.

Indexed as

antimicrobial dosingburninfectionspharmacodynamicspharmacokinetics

Identifiers

PMID41133485
PMCPMC12550937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.